scholarly journals Critical Update on Malignant Salivary Gland Neoplasms

2017 ◽  
Vol 8 (2) ◽  
pp. 71-75
Author(s):  
Natalya Chernichenko
Keyword(s):  
Salivary Gland ◽  
Recent Literature ◽  
Locally Advanced ◽  
Salivary Gland Neoplasms ◽  
Adjuvant Radiation ◽  
Low Grade ◽  
Wide Range ◽  
Locally Advanced Tumors ◽  
Head Neck

ABSTRACT Salivary gland neoplasms are relatively rare tumors with a wide range of biologic behavior. Early low-grade malignancies could be adequately treated with surgery alone, while larger locally advanced tumors will require adjuvant radiation therapy. The role of chemotherapy remains palliative. The goal of this article is to provide a critical review of recent literature on diagnosis and management of salivary neoplasms. How to cite this article Chernichenko N. Critical Update on Malignant Salivary Gland Neoplasms. Int J Head Neck Surg 2017;8(2):71-75.

Έκφραση πρωτεϊνών θερμικού σοκ και νεοαγγειογένεση στα νεοπλάσματα των σιελογόνων αδένων

2013 ◽  
Author(s):  
Βασίλειος Παπανικολάου
Keyword(s):  
Salivary Gland ◽  
Angiogenesis Inhibitor ◽  
Salivary Gland Neoplasms ◽  
Malignant Neoplasms ◽  
Low Grade ◽  
Benign Neoplasms ◽  
Related Molecule ◽  
Collagen Xviii ◽  
Pleomorphic Adenomas ◽  
Endothelial Marker

IntroductionSalivary gland neoplasms comprise a wide group of tumors with diverse histology and broad biologic behavior, often presenting difficulties in their definitive diagnosis and treatment. In the last decades, the prominent role of angiogenesis in the neoplastic process has been recognized, and alterations of its promoters and inhibitors have been investigated in most human tumors. However, angiogenesis in salivary gland neoplasms has not been thoroughly studied.Material and MethodsWe evaluated the immunohistochemical expression of various angiogenesis-related molecules and the vascularity of 61 malignant (16 adenoid cystic carcinomas, 12 mucoepidermoid carcinomas, 11 polymorphous low grade adenocarcinomas, 9 adenocarcinomas NOS, 6 salivary duct carcinomas, 3 carcinomas ex-pleomorphic adenomas, 2 lymphoepithelial carcinomas, 1 myoepithelial carninoma, 1 clear cell carinoma NOS) and 18 benign salivary gland neoplasms (13 pleomorphic adenomas, 5 Warthin tumours).The evaluated molecules were: angiogenesis-promoter vascular endothelial growth factor (VEGF). angiogenesis-inhibitor Endostatin. angiogenesis related molecule collagen angiogenesis related molecule HSP47. endothelial marker FVIIIR:Ag. Vascularity was assessed by calculation of MicroVessel Density (MVD) and by FVIIIR:Ag immunostaining intensity.ResultsVEGF was expressed in 83.6% of malignant and 94.44% of benign neoplasms. Endostatin was expressed in 91.8% and 100% of malignant and benign cases respectively. Collagen XVIII was expressed in 100% of both benign and malignant neoplasms. HSP47 was expressed in 78.68% of malignant and 100% of benign neoplasms.All markers predominantly showed a diffuse pattern of immunostaining (more than 50% positive cells). VEGF immunostaining intensity varied widely among cases, ranging from weak to strong for both malignant and benign cases. Endostatin, Collagen XVIII and HSP47 presented varying immunointensity for malignant cases, whereas benign cases mainly presented strong immunostaining.Statistical analysis correlated VEGF expression in malignant neoplasms with TNM stage and extraparenchymal infiltration (p=0,0005 and 0,00063 respectively). The total score of immunoreactivity for Endostatin, Collagen XVIII and HSP47 was significantly higher in benign compared to malignant cases (p=0.01, p=0.02, and p=0,00996 respectively). Furthermore, HSP47 positivity and intensity was statistically higher in benign neoplasms, compared to malignant (p=0,0067 and p=0.0249 respectively). Additionally Endostatin immunoexpression correlated with Collagen XVIII expression in benign cases (p<0.001). No association was found regarding tumor MVD. However, immunostaining intensity of the endothelial marker FVIIIR:Ag was higher in malignant tumours (p=0,013).ConclusionsOur results show that benign compared to malignant salivary gland neoplasms express higher levels of Endostatin, Collagen XVIII and HSP47. Ιn malignant neoplasms an increase in the ratio of angiogenic to angiostatic elements is observed. It suggested that enhanced angiogenesis may contribute to salivary gland carcinogenesis.

Choroid plexus tumours

2017 ◽  
Author(s):  
Maria Santos ◽  
Eric Bouffet ◽  
Carolyn Freeman ◽  
Mark M. Souweidane
Keyword(s):  
Choroid Plexus ◽  
Choroid Plexus Papilloma ◽  
Choroid Plexus Carcinoma ◽  
Adjuvant Radiation ◽  
Li Fraumeni Syndrome ◽  
Central Nervous System Tumours ◽  
Histological Criteria ◽  
Wide Range ◽  
Plexus Papilloma

Choroid plexus tumours are rare, intraventricular, primary central nervous system tumours derived from the choroid plexus epithelium. They occur predominantly in children and are classified based on histological criteria as choroid plexus papilloma, atypical choroid plexus papilloma, and choroid plexus carcinoma. Choroid plexus carcinomas can occur in the context of Li–Fraumeni syndrome, where the TP53 germline mutation predisposes patients to a wide range of neoplasms. Treatment of these tumours is challenging, due to their high vascularity and the young age of the patients. While surgery is the mainstay of treatment of all choroid plexus tumours, the exact role of adjuvant therapy, particularly in choroid plexus carcinoma, is still unclear. For incompletely resected tumours, there is evidence that neoadjuvant chemotherapy can facilitate second-look surgery and reduce the risk of intraoperative bleeding. However, the role of adjuvant radiation after complete resection remains unclear.

Role of nuclear morphometry in diagnosis of salivary gland neoplasms

2020 ◽  
Vol 48 (12) ◽  
pp. 1181-1193
Author(s):  
Jai Kumar Chaurasia ◽  
Vikas Gupta ◽  
Vipul Mayank ◽  
Ishan Raj Tiwari ◽  
Deepti Joshi ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Salivary Gland Neoplasms ◽  
Nuclear Morphometry

scholarly journals Postoperative Radiation Therapy for Parotid Mucoepidermoid Carcinoma

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Meghan P. Olsen ◽  
Allen O. Mitchell ◽  
Edward F. Miles
Keyword(s):  
Radiation Therapy ◽  
Parotid Gland ◽  
Mucoepidermoid Carcinoma ◽  
Controlled Trials ◽  
Adjuvant Radiation ◽  
Low Grade ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy ◽  
Randomized Controlled

Salivary gland cancers are rare and represent approximately 5% of all head and neck cancers and only 0.3% of all malignancies. The majority (75%) of salivary gland tumors occur in the parotid gland, and while benign lesions are more common, mucoepidermoid carcinoma (MEC) makes up 40–50% of malignant parotid gland tumors. No randomized controlled trials exist regarding the role of adjuvant radiation for patients who undergo surgical resection of low-grade MECs. Herein, we report two cases of successful postoperative radiation therapy in low-grade, pT2N0 MEC of the parotid gland. The role of adjuvant radiation therapy for patients with MEC of the parotid gland is based on data from institution reviews and lacks data from randomized controlled trials. Per our review of the literature, the pathological findings of positive surgical margins and/or perineural invasion in two patients with low-grade MEC of the parotid gland warranted adjuvant radiation for improved local control after partial parotidectomy. Both patients tolerated postoperative radiation therapy with only mild side effects and, at last follow-up, five years after completion of therapy, had no clinical or radiographic evidence of either local recurrence or distant metastasis.

scholarly journals The role of perioperative radiotherapy in gastric cancer

2012 ◽  
Vol 6 (2) ◽  
pp. 23 ◽  
Author(s):  
Thales Paulo Batista ◽  
Lucas Marque De Mendonça ◽  
Ana Luiza Fassizoli-Fonte
Keyword(s):  
Gastric Cancer ◽  
Therapeutic Strategy ◽  
Multimodal Therapy ◽  
Early Stage ◽  
Locally Advanced ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Locally Advanced Tumors ◽  
Related Mortality

Gastric cancer is one of the most common neoplasms and a main cause of cancer-related mortality worldwide. Surgery remains the mainstay for cure and is considered for all patients with potentially curable disease. However, despite the fact that surgery alone usually leads to favorable outcomes in early stage disease, late diagnosis usually means a poor prognosis. In these settings, multimodal therapy has become the established treatment for locally advanced tumors, while the high risk of locoregional relapse has favored the inclusion of radiotherapy in the comprehensive therapeutic strategy. We provide a critical, non-systematic review of gastric cancer and discuss the role of perioperative radiation therapy in its treatment.

The Jumonji family: past, present and future of histone demethylases in cancer

2014 ◽  
Vol 5 (3) ◽  
pp. 209-224 ◽  
Author(s):  
Gianluigi Franci ◽  
Alfonso Ciotta ◽  
Lucia Altucci
Keyword(s):  
Cardiac Disease ◽  
Neurological Disorders ◽  
Recent Literature ◽  
Tube Formation ◽  
Histone Demethylases ◽  
Post Translational Modifications ◽  
Biological Features ◽  
Wide Range ◽  
Expression Modulation

AbstractThe first Jumonji gene was cloned in 1995 by Takeuchi et al. [Takeuchi T, Yamazaki Y, Katoh-Fukui Y, Tsuchiya R, Kondo S, Motoyama J, Higashinakagawa T. Gene trap capture of a novel mouse gene, jumonji, required for neural tube formation. Genes Dev 1995; 9: 1211–22.]. Several genes sharing similar biological features have since been discovered, and are currently grouped into the JMJ family. Interestingly, their deregulation has been associated with cardiac disease, obesity, neurological disorders and cancer. One of the mechanisms underlying their function is gene expression modulation via histone post-translational modifications (PTMs). Increasing evidence of Jumonji deregulation in tumours such as colon, prostate, haematological and breast cancer is continually emerging, hence the need to acquire a better understanding. The Genesapiens.org database of patient arrays allows target expression levels to be investigated in a wide range of cancers, corroborating and extending the role of the JMJ family. Here, we provide an overview of the expression profile and regulation of JMJ family members in cancer, examining the most recent literature in the light of analyses drawn from this database.

Sign in / Sign up

Export Citation Format

Share Document